Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma

  • Urothelial Cancer (A Sagalowsky, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Urothelial carcinoma is a highly heterogeneous disease that can arise throughout the entire urothelial lining from the renal pelvis to the proximal urethra. Upper tract urothelial carcinoma (UTUC) is rare, and while it shares many similarities with urothelial carcinoma of bladder (UCB), there are also significant differences between UTUC and UCB regarding clinical management and outcomes. No major advances have been made recently in the development of new systemic therapies for urothelial carcinoma, partly due to the lack of understanding of underlying molecular pathogenetic mechanisms. In the past decade, the emergence of next-generation sequencing has greatly enabled genomic characterization of tumor samples. Researchers are currently exploring a personalized approach to augment traditional clinical decision-making based on genetic alterations. In the present review, we summarize current genomic advances in UTUC and discuss the potential implications of these developments for developing prognostic and predictive biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Roupret M et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63(6):1059–71.

    Article  PubMed  Google Scholar 

  2. Rigola MA et al. Comparative genomic hybridization analysis of transitional cell carcinomas of the renal pelvis. Cancer Genet Cytogenet. 2001;127(1):59–63.

    Article  CAS  PubMed  Google Scholar 

  3. Misumi T et al. DNA copy number aberrations associated with lymphovascular invasion in upper urinary tract urothelial carcinoma. Cancer Genet. 2012;205(6):313–8.

    Article  CAS  PubMed  Google Scholar 

  4. Sasaki Y et al. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Int J Clin Exp Pathol. 2014;7(2):699–708.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Sfakianos JP et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2015;68(6):970–7. This manuscript is the largest series of UTUC tumors profiled using next- generation sequencing and provided the molecular landscape of UTUC and potential actionable genomic targets in UTUC.

    Article  CAS  PubMed  Google Scholar 

  6. Sijmons RH et al. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol. 1998;160(2):466–70.

    Article  CAS  PubMed  Google Scholar 

  7. Skeldon SC et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013;63(2):379–85.

    Article  CAS  PubMed  Google Scholar 

  8. Umar A et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Amira N et al. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol. 2003;170(4 Pt 1):1151–4.

    Article  PubMed  Google Scholar 

  10. Roupret M et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology. 2005;65(6):1233–7.

    Article  PubMed  Google Scholar 

  11. Catto JW et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23(13):2903–10.

    Article  CAS  PubMed  Google Scholar 

  12. Valeri N et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010;107(15):6982–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Garcia-Tello A et al. DNA repair genes and prognosis in sporadic forms of urothelial carcinoma of the upper urinary tract. Actas Urol Esp. 2014;38(9):600–7.

    Article  CAS  PubMed  Google Scholar 

  14. Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  PubMed  Google Scholar 

  15. Mitchell S, Mayer E, Patel A. Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8(9):516–22. This article critically summarizes previous studies of p53 expression in UTUC and highlights the limitations of sample size, methods to detect p53 expression and statistical analyses.

    Article  CAS  PubMed  Google Scholar 

  16. Rey A et al. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer. 1997;79(11):2178–85.

    Article  CAS  PubMed  Google Scholar 

  17. Hashimoto H et al. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol. 2000;7(12):457–63.

    Article  CAS  PubMed  Google Scholar 

  18. Zigeuner R et al. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology. 2004;63(6):1079–83.

    Article  PubMed  Google Scholar 

  19. Lee YC et al. Prognostic value of p53 protein overexpression in upper tract urothelial carcinomas in Taiwan. Anticancer Res. 2013;33(3):1091–8.

    PubMed  Google Scholar 

  20. Furihata M et al. p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. Int J Cancer. 1995;64(5):298–303.

    Article  CAS  PubMed  Google Scholar 

  21. Furihata M et al. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol. 1996;178(2):133–9.

    Article  CAS  PubMed  Google Scholar 

  22. Bagrodia A et al. Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. Eur Urol. 2012;62(1):e27–9.

    Article  PubMed  Google Scholar 

  23. van Oers JM et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650–7.

    Article  PubMed  Google Scholar 

  24. Lyle SR et al. Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis. Res Rep Urol. 2012;4:65–9.

    PubMed Central  PubMed  Google Scholar 

  25. Lin HH et al. CCND1 1722 polymorphism and potential relevance to upper tract urothelial cancer. Anticancer Res. 2011;31(3):1043–7.

    CAS  PubMed  Google Scholar 

  26. Chang WS et al. Significant association of caveolin-1 (CAV1) genotypes with upper urothelial tract cancer. Anticancer Res. 2013;33(11):4907–12.

    CAS  PubMed  Google Scholar 

  27. Roupret M et al. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol. 2012;187(2):424–8.

    Article  CAS  PubMed  Google Scholar 

  28. Chang WS et al. Significant association of cyclo-oxygenase 2 genotypes with upper tract urothelial cancer. Anticancer Res. 2015;35(5):2725–30.

    CAS  PubMed  Google Scholar 

  29. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286–98.

    Article  CAS  PubMed  Google Scholar 

  30. Phe V, Cussenot O, Roupret M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 2009;104(7):896–901.

    Article  CAS  PubMed  Google Scholar 

  31. Monteiro-Reis S et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer. 2014;50(1):226–33.

    Article  CAS  PubMed  Google Scholar 

  32. Xiong, G., et al., Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics, 2015:1–12.

  33. Inoue K et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002;8(6):1863–70.

    CAS  PubMed  Google Scholar 

  34. Wu CF et al. Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. Br J Cancer. 2010;103(6):852–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Kosaka T et al. Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res. 2010;16(23):5814–23.

    Article  CAS  PubMed  Google Scholar 

  36. Izquierdo L et al. Adhesion molecules alpha, beta and gamma-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT-P/GSK-3beta/beta-catenin pathway. BJU Int. 2009;104(1):100–6.

    Article  CAS  PubMed  Google Scholar 

  37. Leibl S et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS. 2008;116(1):27–32.

    Article  PubMed  Google Scholar 

  38. Wang YW et al. Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway. J Urol. 2014;192(1):242–51.

    Article  CAS  PubMed  Google Scholar 

  39. Izquierdo L et al. HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res. 2010;30(6):2439–45.

    PubMed  Google Scholar 

  40. Qian CN et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res. 2009;69(21):8256–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Liang PI et al. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol. 2013;66(7):573–82.

    Article  CAS  PubMed  Google Scholar 

  42. Munari E et al. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Hum Pathol. 2013;44(12):2668–76.

    Article  CAS  PubMed  Google Scholar 

  43. Nakanishi K et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res. 2005;11(7):2583–90.

    Article  CAS  PubMed  Google Scholar 

  44. Krabbe LM et al. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. J Urol. 2014;191(1):28–34.

    Article  CAS  PubMed  Google Scholar 

  45. Kamai T et al. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int. 2000;86(1):14–9.

    Article  CAS  PubMed  Google Scholar 

  46. Bagrodia A et al. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology. 2014;84(5):1134–40.

    Article  PubMed  Google Scholar 

  47. Yeh HC et al. Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. BJU Int. 2010;106(8):1223–9.

    Article  PubMed  Google Scholar 

  48. Scarpini S et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol. 2012;30(2):182–7.

    Article  CAS  PubMed  Google Scholar 

  49. Uematsu K et al. Glucose-regulated protein 78 expression in urothelial carcinoma of the upper urinary tract. BJU Int. 2010;106(6):873–8.

    Article  PubMed  Google Scholar 

  50. Jeong IG et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol. 2009;40(5):668–77.

    Article  CAS  PubMed  Google Scholar 

  51. Wu S et al. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma. BMC Cancer. 2014;14:836.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Lu CM et al. A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis. BMC Cancer. 2014;14:363.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Iyer G et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Kurtoglu M et al. Elevating the horizon: emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma. Clin Genitourin Cancer. 2015;13(5):410–20. This article reviewed emerging genomic targets, most promising targeted therapies and novel clinical trial designs for urothelial carcinoma of bladder.

    Article  PubMed  Google Scholar 

  55. Smith SC et al. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010;70(5):1753–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. S Kothari, D. Gustatafson, K Killian, J Costello, D C. Edelman, J Walling, P S. Meltzer, D Theodorescu, A Borghese. COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients. J Clin Oncol. 2015;33(suppl; abstr e15533).

Download references

Author information

Authors and Affiliations

  1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Qiang Li, Aditya Bagrodia, Eugene K. Cha & Jonathan A. Coleman

  2. Urology Service, Department of Surgery, Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 353 E. 68th Street, New York, NY, 10065, USA

    Jonathan A. Coleman

Authors
  1. Qiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aditya Bagrodia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugene K. Cha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan A. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan A. Coleman.

Ethics declarations

Conflict of Interest

Qiang Li, Aditya Bagrodia, Eugene K. Cha, and Jonathan A. Coleman each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Urothelial Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Q., Bagrodia, A., Cha, E.K. et al. Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. Curr Urol Rep 17, 12 (2016). https://doi.org/10.1007/s11934-015-0566-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-015-0566-y

Keywords

Search

Navigation